What this is
- How it works
- How it works isn't classified yet
- Tested for
- Locally Advanced Rectal Cancer (LARC)
- Main trialPhase 1
- “The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.”In the company’s words, NCT06459869 on ClinicalTrials.gov
Coming up1
- 30 Jan 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 30 Jan 2027 | NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer | |
| Phase 1Completed | 4 Feb 2022 | First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) | |
| Phase 1Completed | 12 Nov 2024 | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026